Laird Norton Wetherby Wealth Management’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$237K Buy
1,517
+6
+0.4% +$953 0.01% 825
2025
Q2
$229K Buy
+1,511
New +$201K 0.01% 819
2024
Q4
$296K Sell
1,603
-68
-4% -$13.1K 0.01% 704
2024
Q3
$329K Sell
1,671
-36
-2% -$7.48K 0.02% 698
2024
Q2
$353K Hold
1,707
0.02% 652
2024
Q1
$463K Sell
1,707
-73
-4% -$17.4K 0.02% 584
2023
Q4
$421K Buy
1,780
+10
+0.6% +$1.97K 0.02% 604
2023
Q3
$347K Sell
1,770
-139
-7% -$28.5K 0.02% 635
2023
Q2
$401K Buy
1,909
+8
+0.4% +$1.59K 0.02% 616
2023
Q1
$384K Sell
1,901
-26
-1% -$5.89K 0.02% 625
2022
Q4
$420K Buy
1,927
+23
+1% +$5.02K 0.03% 575
2022
Q3
$375K Sell
1,904
-46
-2% -$9.93K 0.03% 581
2022
Q2
$417K Buy
1,950
+157
+9% +$38.4K 0.03% 555
2022
Q1
$509K Buy
1,793
+44
+3% +$13.6K 0.03% 515
2021
Q4
$659K Sell
1,749
-188
-10% -$73K 0.04% 423
2021
Q3
$799K Sell
1,937
-13
-0.7% -$5.4K 0.05% 357
2021
Q2
$721K Buy
+1,950
New +$651K 0.04% 387
2021
Q1
Sell
-1,935
Closed -$483K 802
2020
Q4
$483K Buy
+1,935
New +$461K 0.03% 473

Other funds holding CRL

Laird Norton Wetherby Wealth Management's CRL Position: Q3 2025 in Review

Laird Norton Wetherby Wealth Management increased its Charles River Laboratories (CRL) stake by 0.4% in Q3 2025, buying an estimated $953 and bringing the position to 1,517 shares worth $237K. The position accounts for 0.01% of the portfolio, ranked #825.

Laird Norton Wetherby Wealth Management first reported a position in CRL in Q4 2020 and has held it in 18 quarters since. The position peaked at $799K in Q3 2021. 556 funds tracked by Wall St. Rank hold CRL as of Q3 2025.

  • Laird Norton Wetherby Wealth Management held 1,517 shares of Charles River Laboratories worth $237K as of Q3 2025.
  • Laird Norton Wetherby Wealth Management bought 6 Charles River Laboratories shares in Q3 2025, an estimated $953.
  • Charles River Laboratories made up 0.01% of Laird Norton Wetherby Wealth Management's portfolio in Q3 2025, its #825 holding.
  • Laird Norton Wetherby Wealth Management first reported a position in Charles River Laboratories in Q4 2020 and has held it in 18 quarters since.
  • Laird Norton Wetherby Wealth Management's Charles River Laboratories position peaked at $799K in Q3 2021.
  • 556 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2025.

Based on Laird Norton Wetherby Wealth Management's 13F filing for Q3 2025, filed 14 Nov 2025.